8-KEarnings & ResultsExhibits & Filings

ELI LILLY & Co 8-K Report, Financial Results (Oct 23, 2013)

Filed October 23, 2013For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on October 23, 2013, to report its third quarter and nine-month financial results for the period ending September 30, 2013. The filing primarily directs investors to a press release (Exhibit 99.1) and a teleconference for detailed information regarding operational and financial performance. Notably, the company highlighted its use of non-GAAP financial measures, such as non-GAAP net income and earnings per share, in its reporting. Lilly explained that these measures are intended to provide investors with a clearer view of ongoing operations by excluding highly variable and unpredictable items that could distort reported results. Management also utilizes these non-GAAP metrics for internal performance evaluation and resource allocation.

Key Highlights

  • 1Company reported third quarter and nine-month financial results as of September 30, 2013.
  • 2Detailed financial results are available via a press release (Exhibit 99.1) and a subsequent analyst teleconference.
  • 3Lilly utilizes non-GAAP financial measures (e.g., non-GAAP net income, EPS) in its reporting.
  • 4Non-GAAP measures are used to provide investors with insights into ongoing operations by excluding unpredictable items.
  • 5Management uses non-GAAP measures for internal performance evaluation and resource allocation.
  • 6The company cautions that non-GAAP measures should be considered alongside, not as a substitute for, GAAP measures.
  • 7Prospective earnings guidance is subject to adjustments for unpredictable future matters.

Frequently Asked Questions

The main purpose of this 8-K filing is to report Eli Lilly and Company's financial results for the third quarter and the first nine months of 2013, which concluded on September 30, 2013. It directs investors to a press release and a teleconference for the specifics of these results.

Eli Lilly uses non-GAAP financial measures to provide investors with a clearer view of its ongoing operational performance. These measures exclude items that are typically highly variable, difficult to predict, and could significantly impact reported results, thereby aiding in meaningful period-over-period comparisons and trend identification.

No, Eli Lilly explicitly states that investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. They are intended to supplement, not replace, the standard accounting measures.

The detailed financial results for the third quarter and nine-month period ended September 30, 2013, are provided in the press release attached as Exhibit 99.1 to this 8-K filing. The company also held a teleconference to discuss these results.